-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Greenwich LifeSciences, Inc. (NASDAQ:GLSI) Short Interest Update
Greenwich LifeSciences, Inc. (NASDAQ:GLSI) Short Interest Update
Greenwich LifeSciences, Inc. (NASDAQ:GLSI – Get Rating) saw a significant increase in short interest in the month of December. As of December 30th, there was short interest totalling 224,600 shares, an increase of 15.6% from the December 15th total of 194,300 shares. Approximately 6.2% of the company's shares are sold short. Based on an average trading volume of 42,500 shares, the days-to-cover ratio is currently 5.3 days.
Insider Buying and Selling
In other Greenwich LifeSciences news, CEO Snehal Patel bought 2,000 shares of the firm's stock in a transaction that occurred on Friday, December 9th. The stock was acquired at an average price of $13.11 per share, with a total value of $26,220.00. Following the completion of the purchase, the chief executive officer now directly owns 2,724,886 shares of the company's stock, valued at approximately $35,723,255.46. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders have purchased a total of 8,250 shares of company stock valued at $104,275 over the last ninety days. 52.14% of the stock is owned by company insiders.
Get Greenwich LifeSciences alerts:Institutional Investors Weigh In On Greenwich LifeSciences
Several hedge funds and other institutional investors have recently modified their holdings of the stock. Vanguard Group Inc. lifted its stake in Greenwich LifeSciences by 150.2% during the first quarter. Vanguard Group Inc. now owns 375,200 shares of the company's stock worth $7,362,000 after purchasing an additional 225,213 shares during the last quarter. Renaissance Technologies LLC purchased a new position in shares of Greenwich LifeSciences in the 2nd quarter valued at approximately $891,000. Millennium Management LLC bought a new stake in shares of Greenwich LifeSciences during the 2nd quarter valued at $765,000. Occudo Quantitative Strategies LP bought a new stake in Greenwich LifeSciences during the second quarter worth about $199,000. Finally, Pura Vida Investments LLC bought a new stake in shares of Greenwich LifeSciences in the 3rd quarter worth approximately $179,000. 6.18% of the stock is currently owned by institutional investors.
Greenwich LifeSciences Trading Up 2.1 %
Shares of GLSI traded up $0.37 on Monday, reaching $17.83. The company's stock had a trading volume of 18,542 shares, compared to its average volume of 33,867. Greenwich LifeSciences has a twelve month low of $6.82 and a twelve month high of $26.27. The firm has a fifty day moving average of $13.91 and a 200-day moving average of $10.96. The stock has a market capitalization of $228.65 million, a PE ratio of -30.63 and a beta of 0.66.Greenwich LifeSciences (NASDAQ:GLSI – Get Rating) last posted its quarterly earnings results on Monday, November 14th. The company reported ($0.18) earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.01. As a group, equities analysts anticipate that Greenwich LifeSciences will post -0.57 EPS for the current fiscal year.
About Greenwich LifeSciences
(Get Rating)
Greenwich LifeSciences, Inc, a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.
Further Reading
- Get a free copy of the StockNews.com research report on Greenwich LifeSciences (GLSI)
- Is Wayfair Still Way Cheap For Investors?
- When Does Pfizer Become A Bargain?
- Tractor Supply Company Shares Could be Headed to New Highs
- Is Canadian Solar Too Hot to Handle?
- UiPath is the Blue-Collar AI Platform to Watch in 2023
Receive News & Ratings for Greenwich LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Greenwich LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.
Greenwich LifeSciences, Inc. (NASDAQ:GLSI – Get Rating) saw a significant increase in short interest in the month of December. As of December 30th, there was short interest totalling 224,600 shares, an increase of 15.6% from the December 15th total of 194,300 shares. Approximately 6.2% of the company's shares are sold short. Based on an average trading volume of 42,500 shares, the days-to-cover ratio is currently 5.3 days.
格林威治生命科学公司(纳斯达克股票代码:GLSI — GET Ratinge)在12月份的空头利率大幅增加。截至12月30日,空头利率共计224,600股,较12月15日的194,300股增长了15.6%。该公司约有6.2%的股票被卖空。根据42,500股的平均交易量,目前的天数与覆盖率为5.3天。
Insider Buying and Selling
内幕买入和卖出
In other Greenwich LifeSciences news, CEO Snehal Patel bought 2,000 shares of the firm's stock in a transaction that occurred on Friday, December 9th. The stock was acquired at an average price of $13.11 per share, with a total value of $26,220.00. Following the completion of the purchase, the chief executive officer now directly owns 2,724,886 shares of the company's stock, valued at approximately $35,723,255.46. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders have purchased a total of 8,250 shares of company stock valued at $104,275 over the last ninety days. 52.14% of the stock is owned by company insiders.
在格林威治生命科学的其他新闻中,首席执行官斯内哈尔·帕特尔在12月9日星期五进行的一笔交易中购买了该公司的2,000股股票。该股以每股13.11美元的平均价格收购,总价值为26,220.00美元。收购完成后,首席执行官现在直接拥有该公司2724,886股股票,价值约为35,723,255.46美元。此次收购是在向美国证券交易委员会提交的法律文件中披露的,该文件可在以下网址查阅 这个超链接。在过去的九十天里,内部人士共购买了价值104,275美元的8,250股公司股票。52.14%的股票由公司内部人士持有。
Institutional Investors Weigh In On Greenwich LifeSciences
机构投资者关注格林威治生命科学
Several hedge funds and other institutional investors have recently modified their holdings of the stock. Vanguard Group Inc. lifted its stake in Greenwich LifeSciences by 150.2% during the first quarter. Vanguard Group Inc. now owns 375,200 shares of the company's stock worth $7,362,000 after purchasing an additional 225,213 shares during the last quarter. Renaissance Technologies LLC purchased a new position in shares of Greenwich LifeSciences in the 2nd quarter valued at approximately $891,000. Millennium Management LLC bought a new stake in shares of Greenwich LifeSciences during the 2nd quarter valued at $765,000. Occudo Quantitative Strategies LP bought a new stake in Greenwich LifeSciences during the second quarter worth about $199,000. Finally, Pura Vida Investments LLC bought a new stake in shares of Greenwich LifeSciences in the 3rd quarter worth approximately $179,000. 6.18% of the stock is currently owned by institutional investors.
一些对冲基金和其他机构投资者最近修改了该股的持有量。Vanguard Group Inc.在第一季度将其在格林威治生命科学的股份提高了150.2%。Vanguard Group Inc.在上个季度又购买了225,213股股票后,现在拥有该公司375,200股股票,价值7,362,000美元。Renaissance Technologies LLC在第二季度购买了格林威治生命科学股票的新头寸,价值约89.1万美元。Millennium Management LLC在第二季度购买了格林威治生命科学的新股份,价值76.5万美元。Occudo Quantical Strategies LP在第二季度收购了格林威治生命科学的新股份,价值约19.9万美元。最后,Pura Vida Investments LLC在第三季度购买了格林威治生命科学股票的新股份,价值约17.9万美元。该股票的6.18%目前由机构投资者持有。
Greenwich LifeSciences Trading Up 2.1 %
格林威治生命科学交易上涨2.1%
Greenwich LifeSciences (NASDAQ:GLSI – Get Rating) last posted its quarterly earnings results on Monday, November 14th. The company reported ($0.18) earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.01. As a group, equities analysts anticipate that Greenwich LifeSciences will post -0.57 EPS for the current fiscal year.
格林威治生命科学(纳斯达克股票代码:GLSI — 获取评级)最后一次公布季度财报是在11月14日星期一。该公司公布了本季度每股收益(0.18美元),比市场普遍预期的0.19美元(0.19美元)高出0.01美元。作为一个整体,股票分析师预计,格林威治生命科学将在本财年公布每股收益为-0.57。
About Greenwich LifeSciences
关于格林威治生命科学
(Get Rating)
(获取评分)
Greenwich LifeSciences, Inc, a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.
Greenwich LifeSciences, Inc是一家临床阶段的生物制药公司,专注于开发针对乳腺癌和其他表达HER2/NEU的癌症的新型癌症免疫疗法。其主要候选产品是免疫疗法GP2,它已完成IIb期临床试验,旨在预防先前接受过手术的患者复发乳腺癌。
Further Reading
进一步阅读
- Get a free copy of the StockNews.com research report on Greenwich LifeSciences (GLSI)
- Is Wayfair Still Way Cheap For Investors?
- When Does Pfizer Become A Bargain?
- Tractor Supply Company Shares Could be Headed to New Highs
- Is Canadian Solar Too Hot to Handle?
- UiPath is the Blue-Collar AI Platform to Watch in 2023
- 免费获取 StockNews.com 关于格林威治生命科学 (GLSI) 的研究报告
- 对于投资者来说,Wayfair还便宜吗?
- 辉瑞何时成为便宜货?
- 拖拉机供应公司的股价可能会创下新高
- 加拿大太阳能太热了没法应付吗?
- UiPath 是 2023 年值得关注的蓝领人工智能平台
Receive News & Ratings for Greenwich LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Greenwich LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.
接收《格林威治生命科学日报》的新闻和评级 -在下面输入您的电子邮件地址,即可通过Marketbeat.com的免费每日电子邮件时事通讯接收格林威治生命科学及相关公司的最新新闻和分析师评级的简明每日摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧